Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS outlook to $3.29 – $3.33 versus an estimate of $3.24.
Apple’s ‘Scary Fast’ Event Underwhelms Analysts, Leads To Question Of Timing Ahead Of Q4 Earnings
Apple's "odd timing" causes us to worry that laptop and iMac sales were weak in the Sept. Q," Needham analysts said.
